Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering's shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia ...

Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in a deal that gives Merck key new businesses, access to a promising pipeline of new products and the chance to further cut costs ...

WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that their ...

NEW YORK (CBS.MW) -- Shares of Schering-Plough climbed Tuesday after some analysts said a new cholesterol-lowering drug could help the company recover from its current regulatory and financial woes.

Schering-Plough Corp.’s fourth-quarter earnings surged 62% as the combined sales of its Vytorin and Zetia cholesterol drugs jumped to $1.1 billion. Net income rose to $204 million, or 12 cents a ...

Make this really serious: Investigation and Inquiries. Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its joint venture partner, Merck, have received a number of ...

Schering-Plough said late Wednesday that Richard Jay Kogan will retire as chief executive and president by April 22, 2003. The drugmaker added that, as of Wednesday, Kogan has resigned his ...

KENILWORTH, N.J. Schering-Plough has completed its buyout of the biopharmaceutical company Organon BioSciences NV for about $14.43 billion in cash. This is the completion of a deal first announced ...

Merck and Schering-Plough are scheduled to finalize their merger later today, marking a major consolidation of two venerable New Jersey drug makers. As the companies launch their combined ...

TRENTON, N.J. — Merck, the American pharmaceutical giant, is buying rival Schering-Plough for $41.1 billion in a deal that gives Merck key new businesses, access to a promising pipeline of new ...